DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Information source: Bristol-Myers Squibb
Information obtained from ClinicalTrials.gov on May 09, 2007
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Nelfinavir mesylate (Drug); Lamivudine (Drug); Stavudine (Drug); Zidovudine (Drug); Didanosine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bristol-Myers Squibb

Official(s) and/or principal investigator(s):
. ., Principal Investigator, Affiliation: .

Summary

The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long these drug combinations are effective in lowering viral load (level of HIV in the blood).

Clinical Details

Official title: A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects

Study design: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics Study

Eligibility

Minimum age: 12 Years. Gender(s): Both.

Criteria:

Inclusion Criteria

Patients must have:

Within 15 business days prior to randomization:

- CD4 cell count greater than or equal to 100 cells/mm3.

- HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

- Bilateral peripheral neuropathy.

- Intractable diarrhea.

- Proven or suspected acute hepatitis within 30 days prior to study entry.

Concurrent Medication:

Excluded:

- Therapy for any co-existing disease that may interfere with patient ability to participate in this study.

Concurrent Treatment:

Excluded:

Therapy for any co-existing disease that may interfere with patient ability to participate in this study.

Patients with the following prior conditions are excluded:

History of acute or chronic pancreatitis.

Prior Medication:

Excluded:

- Therapy for any previous disease that may interfere with patient ability to participate in this study.

- Excluded within 14 days prior to randomization:

Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy.

- Excluded within 3 months of the start of this study or expected need at time of enrollment:

- Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential.

- Inability to tolerate oral medication.

Prior Treatment:

Excluded:

Therapy for any previous disease that may interfere with patient ability to participate in this study.

Risk Behavior:

Excluded:

Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.

Locations and Contacts

Sorra Research Ctr / Med Forum, Birmingham, Alabama 35203, United States

Body Positive, Phoenix, Arizona 85016, United States

Harbor UCLA Med Ctr / Research and Educational Institute, Torrance, California 90502, United States

UCLA Med Ctr / CARE BH-412 CHS, Los Angeles, California 90024, United States

West Los Angeles VAMC, Los Angeles, California 90073, United States

Sherman Oaks Hosp Research Institute, Sherman Oaks, California 91403, United States

Hill Top Research Inc, Fresno, California 93710, United States

AIDS Healthcare Foundation, Los Angeles, California 900276069, United States

Yale New Haven Hosp / Nathan Smith Clinic, New Haven, Connecticut 06504, United States

GW Med Ctr / Clinical Trials Unit, Washington, District of Columbia 20037, United States

Saint Josephs Hosp, Tampa, Florida 33602, United States

Hillsborough County Health Dept, Tampa, Florida 33602, United States

Med Alternatives, Fort Lauderdale, Florida 33308, United States

Specialty Med Care Ctrs of South Florida Inc, Miami, Florida 33142, United States

Urgent Care Ctr, Fort Lauderdale, Florida 33316, United States

Rush Presbyterian / ST Lukes Med Ctr, Chicago, Illinois 60612, United States

Northwestern Univ / Div of Infect Diseases, Chicago, Illinois 60611, United States

Univ of Kansas School of Medicine / Office of Rsch, Wichita, Kansas 67214, United States

Ky Clinic Annex #4 / Room 205E / Speed Sort #0284, Lexington, Kentucky 405360226, United States

Dartmouth-Hitchcock Med Ctr, Lebanon, New Hampshire 03756, United States

Infectious Disease Assoc of Central Jersey, Somerville, New Jersey 08876, United States

NJCRI, Newark, New Jersey 07103, United States

SUNY at Stony Brook / Div of Infectious Disease, Stony Brook, New York 117948153, United States

St Luke Roosevelt Hosp, New York, New York 10011, United States

UCT International, Farmingdale, New York 11735, United States

St Mary's Hosp (Univ of Rochester/Infectious Diseases), Rochester, New York 14642, United States

Nalle Clinic / Clinical Research Dept, Charlotte, North Carolina 28207, United States

Associates in Med and Mental Health, Tulsa, Oklahoma 74114, United States

Stephen P Hauptman, Philadelphia, Pennsylvania 19107, United States

Med Univ of South Carolina / Div of Infect Disease, Charleston, South Carolina 29425, United States

Univ of Texas / Med Branch at Galveston, Galveston, Texas 775550835, United States

Joseph C Gathe, Houston, Texas 77004, United States

Additional Information

Starting date: March 1998
Ending date: March 1998
Last updated: June 30, 2005

Page last updated: May 09, 2007

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009